Phase I Study of KPT330 in Asian Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

March 20, 2020

Study Completion Date

March 20, 2020

Conditions
Solid Tumors
Interventions
DRUG

KPT-330

Each dose will consist of KPT-330 (Selinexor) for oral administration on an mg/m2 basis, and should be based on the patient's actual calculated body surface area (BSA) at baseline. Patients with a BSA \>2.5 m(2) will receive a dose based upon a 2.5 m(2) BSA.

Trial Locations (1)

119228

National University Hospital, Singapore

Sponsors
All Listed Sponsors
collaborator

Karyopharm Therapeutics Inc

INDUSTRY

lead

National University Hospital, Singapore

OTHER